EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSMMNG00015020682
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSMMNG00015014507
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSMMNG00015003229
Gene Symbol: NR3C1
3 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSMMNG00015017740
Gene Symbol: NR3C2
1 Cross references
212 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSMMNG00015009637
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSMMNG00015012577
Gene Symbol: OPRD1
3 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSMMNG00015015726
Gene Symbol: OPRK1
3 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSMMNG00015009889
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSMMNG00015004636
Gene Symbol: OPRL1
1 Cross references
199 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSMMNG00015021973
Gene Symbol: OXTR
3 Cross references
262 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSMMNG00015000314
Gene Symbol: PAK4
3 Cross references
163 Possible Orthologues:

Pancreatic Alpha-Amylase

Ensembl ID : ENSMMNG00015005108
Gene Symbol: LOC114899714
2 Cross references
213 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).